1325 G Street, N.W.
Washington, DC 20005
The Law Offices of David A. Balto provides counsel to companies on a broad range of antitrust matters and frequently represents parties before the Antitrust Division of the Department of Justice, the Federal Trade Commission, Congress and state legislatures.
The Law Offices of David Balto counsels a wide variety of Fortune 500 companies, small business and consumer advocates on antitrust and consumer protection compliance, strategic alliances, distribution issues, mergers and joint ventures. With decades of antitrust practice in each of the enforcement agencies and private practice, we effectively represent a broad range of consumer organizations, generic pharmaceutical and medical device manufactures, healthcare providers, retailers, financial services and high technology firms. We are regularly involved in many of the most high-profile government antitrust investigations and cutting-edge class-action litigation. We frequently provide representation for parties in the most sophisticated matters before the Antitrust Division of the Department of Justice, the Federal Trade Commission, Congress and state legislatures.
David Balto wins John Helmuth Award from the Organization for Competitive Markets. Click here to read more.
January 10, 2017 - David Balto discusses why PBMs' pricing policies are likely to get additional scrutiny under the new Presidential administration in P&T Community.
January 9, 2017 - The New York Times quotes David Balto on the problems of PBMs squeezing out specialty pharmacies from the market.
November 21, 2016 - Law Offices of David Balto filed an amicus brief with the Second Circuit Court of Appeals in United States v. American Express Co. on behalf of 23 leading antitrust professors in support of the Department of Justice's petition for rehearing urging the Court to reconsider its ruling allowing AMEX's anticompetitive steering rules. View brief here.
November 8, 2016 - Law Offices of David Balto filed an amicus brief with the First Circuit in Amphastar Pharmaceuticals v. Momenta Pharmaceuticals on behalf of consumer groups Consumer Action, National Health Law Program, and US PIRG urging the court to overturn the District Court's ruling expanding Noerr-Pennington antitrust immunity to cover private standard setting activity. View Here. View related article, January 11, 2017.
November 3, 2016 - David Balto published an article in Law360 discussing why the Third Circuit Court of Appeals should rehear the Doryx product-hopping drug case. View Here.
July 7, 2016 - David Balto in conjunction with 6 national consumer groups release a paper on why remedies will be difficult in the Aetna-Humana and Anthem-Cigna mergers. View Here.
August 17, 2015 - David Balto and James Kovacs discuss why DOJ should block the latest announced health insurance mergers. View Here.
July 24, 2015 - David Balto and James Kovacs published an article in Competition Policy International Antitrust Chronicle discussing current competition issues in healthcare provider merger antitrust. View Here.
July 23, 2015 - David Balto talks to Bloomberg TV about Anthem-CIGNA and antitrust implications of the health insurance mergers. View Here.
July 15, 2015 - David Balto is quoted in NYT article articulating the harmful practices of pharmacy benefit managers in specialty pharmacy. View Here.
February 19, 2015 - David Balto files an amicus brief on behalf of consumer groups supporting New Yorks fight against product hopping. View Here.